Suppr超能文献

A32390A,一种新的生物活性代谢产物。III. 体外和体内抗真菌活性。

A32390A, a new biologically active metabolite. III. In vitro and in vivo antifungal activity.

作者信息

Turner J R, Butler T F, Gordee R S, Thakkar A L

出版信息

J Antibiot (Tokyo). 1978 Jan;31(1):33-7. doi: 10.7164/antibiotics.31.33.

Abstract

A32390A, an isonitrile-containing derivative of mannitol, represents a new class of antifungal antibiotics. In vitro antifungal activity of A32390A was found against Candida albicans, Cryptococcus neoformans and Histoplasma capsulatum. In vivo antifungal activity of A32390A was demonstrated in mice infected with C. albicans. Accumulative doses of 37.5 approximately 600 mg/kg, administered subcutaneously over a 24-hour period, showed significant activity without demonstrating toxicity. A32390A was effective, but not as effective as amphotericin B, in reducing the number of Candida cells isolated from the kidney of infected mice. Urinary excretion of A32390A accounted for only 10% of the administered dose. Improved bioavailability of A32390A was accomplished when the antibiotic was combined with polyvinyl pyrrolidone (PVP) in a solid dispersion. Administration of A32390A as a 10% dispersion in PVP resulted in increased urinary excretion of the drug and reduced the amount of drug required for in vivo activity.

摘要

A32390A是一种含异腈基的甘露醇衍生物,代表了一类新型抗真菌抗生素。已发现A32390A对白色念珠菌、新型隐球菌和荚膜组织胞浆菌具有体外抗真菌活性。A32390A在感染白色念珠菌的小鼠体内表现出抗真菌活性。在24小时内皮下注射累积剂量约37.5至600mg/kg,显示出显著活性且无毒性。在减少从感染小鼠肾脏分离出的念珠菌细胞数量方面,A32390A有效,但不如两性霉素B有效。A32390A的尿排泄量仅占给药剂量的10%。当抗生素与聚乙烯吡咯烷酮(PVP)以固体分散体形式组合时,A32390A的生物利用度得到改善。以10%的PVP分散体形式给药A32390A导致药物尿排泄增加,并减少了体内活性所需的药物量。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验